ASPEN-01: A Phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab, and paclitaxel in patients with 2nd line HER2-positive advanced gastric or gastroesophageal cancer

Son't eat me

Conference Call

July 06, 2021

DISCLAIMER

This presentation contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this presentation. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Report on Form 10-K and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

This presentation also contains estimates and other statistical data made by independent parties and by ALX Oncology relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of ALX Oncology's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.



OVERVIEW

ALX Oncology (Nasdaq: ALXO) is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system Lead product candidate ALX148 initiating multiple Phase 2 trials


CD47 blocker

- Designed for use in combination
- Tolerability profile enables higher dosing
- Higher dosing may enable greater efficacy

Clinical proof-of-principle in both hematologic and solid tumors


Initial focus on solid tumors, MDS, and AML

CD47: TUMOR ASSOCIATED ANTIGEN (TAA)- MYELOID CHECKPOINT DUALITY



TAA-Expression levels on cancer and normal cells

Checkpoint Mechanism: "do not eat me"




TARGETING CD47 AS TUMOR ASSOCIATED ANTIGEN

Macrophage Cancer cell Fc receptor CD47 Anti-CD47 SIRPa

Anti CD47 with active Fc directly targets cancer cells

ALX [•]NCOLOGY But also targets normal cells




Dose limitations prevent full blockade of CD47 and active Fc competes with combo drug

5

TARGETING CD47 AS CHECKPOINT: ALX ONCOLOGY'S APPROACH

It spares normal cells



Anti CD47 with inactive Fc binds and block CD47-SIRP α interaction


ALX

ØNCOLOGY

High dose allows full blockade of CD47 and maximizes activity of combo drug

ALX148 POTENTLY AND SELECTIVELY BINDS CD47 TO BLOCK SIRP α INTERACTION

High affinity CD47 binding domains of SIRPα




• Fc domain enables antibody-like PK.

• Molecular weight half the size of typical antibody.

Inactive Fc domain

GASTRIC CANCER (GC) TRIAL: ALX148 + HERCEPTIN MECHANISM OF ACTION



ALX148 increases antibody dependent cellular phagocytosis in combination with Herceptin

ALX ØNCOLOGY

ASPEN-01: A PHASE 1 STUDY OF ALX148, A CD47 BLOCKER, IN COMBINATION WITH TRASTUZUMAB, RAMUCIRUMAB, AND PACLITAXEL IN PATIENTS WITH 2ND LINE HER2-POSITIVE ADVANCED GASTRIC OR GASTROESOPHAGEAL CANCER

Hyun Cheol Chung,^{1*} Keun-Wook Lee,^{2*} Won Seog Kim,³ Justin Gainor,⁴ Nehal Lakhani,⁵ Laura QM Chow,^{6**} Wells Messersmith,⁷ Philip Fanning,⁸ Pierre Squifflet,⁹ Feng Jin,⁸ Alison Forgie,⁸ Hong Wan,⁸ Jaume Pons,⁸ Sophia Randolph,⁸ Patricia LoRusso¹⁰

¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; ²Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea; ³Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; ⁴Massachusetts General Hospital, Boston, MA; ⁵START Midwest, Grand Rapids, MI; ⁶University of Washington, Seattle, WA; ⁷University of Colorado Cancer Center, Aurora, CO; ⁸ALX Oncology Inc, Burlingame, CA, USA, ⁹International Drug Development Institute, Brussels, Belgium, ¹⁰Yale Cancer Center, New Haven, CT

*HCC and KWL contributed equally to this abstract; **LQMC currently at University of Texas at Austin, TX.

METHODS STUDY DESIGN

Part 1 (single agent): Patients were administered escalating doses of intravenous ALX148 (0.3 to 10 mg/kg QW; or 30 mg/kg Q2W)³.

Part 2 (combination): A subgroup of patients with HER2 positive Gastric/GEJ cancer were administered ALX148 10 or 15 mg/kg QW in combination with trastuzumab (8 mg/kg IV \rightarrow 6 mg/kg Q3W) with or without ramucirumab (8 mg/kg Days 1, 15 Q4W) and paclitaxel (80 mg/m2 Days 1, 8, 15 Q4W).

- Adequate organ function and hemoglobin $\geq 9 \text{ g/dL}$.
- No prior treatment with an anti-CD47 or anti-SIRPα agent.
- HER2-positive-status for study eligibility as locally assessed by sites using an FDA approved test for gastric cancer.

Primary: Safety DLT

Secondary: Response, PK/PD

Here we report tolerability data from fully enrolled GC patient cohorts receiving ALX148 + trastuzumab + ramucirumab + paclitaxel as well as updated clinical activity of all GC cohorts as of May 03, 2021.

ASPEN-01 – Gastric/Gastroesophageal (GC) Combination Cohorts

Dose Expansion ALX148 10 mg/kg QW (n=20)

≥2L HER2-Positive GC ALX148 + Trastuzumab

progressed on prior fluoropyrimidine (progression on trastuzumab and platinum allowed)



Dose Escalation ALX148 10 mg/kg QW (n=3) 15 mg/kg QW (n=15)

≥2L HER2-Positive GC ALX148 + Trastuzumab + Ramucirumab + Paclitaxel progressed on prior trastuzumab and fluoropyrimidine, or platinum

ALX ØNCOLOGY

RESULTS PATIENT BASELINE CHARACTERISTICS

 Table 1. Baseline Characteristics

		ALX148 + Trastuzumab + Ramucirumab + Paclitaxel ≥2L GC (N=18)	ALX148 + Trastuzumab ≥2L GC (N=20)	
Median Age, Years (range)		63 (36-83)	58 (45-79)	
Sex, n	м	13	15	
	F	5	5	
Race, n	Asian	15	13	
	White	3	6	
	Other	- 1.4	1	
ECOG PS, n	0	8	7	
	1	10	13	
Progressed Upon Prior Anti-HER2 Therapy, n (%)		17 (94)	19 (95)	
Progressed Upon ≥2 Prior Anti-HER2 Therapy n (%)		1 (6)	9 (45)	
Progressed Upon Prior CPI Therapy, n (%)		2 (11)	9 (45)	
Visceral Distant Metastasis, n (%)		17 (94)	17 (85)	

 38 patients have been enrolled into Part 2 GC combination cohorts.

ADVERSE EVENT PROFILE IN PATIENTS WITH GC BY DOSE LEVEL

 Table 2. Treatment Related Adverse Events

ALX148 + Trastuzumab + Ramucirumab + Paclitaxel (N=18)

(14-10)					
Total n (%)					
ALX148	ALX148				
10 mg/kg	15 mg/kg				
-	3 (16.7)				
_	3 (16.7)				
_	3 (16.7)				
-	2 (11.1)				
1 (5.6)	1 (5.6)				
-	1 (5.6)				
-	1 (5.6)				
	1 (5.6)				
-	1 (5.6)				
_	1 (5.6)				
-	1 (5.6)				
_	1 (5.6)				
	Total ALX148 10 mg/kg - - - - -				

• There were no dose limiting toxicities, on study deaths, or ALX148-related SAEs.

ADVERSE EVENT PROFILE IN PATIENTS WITH GC BY DOSE LEVEL

1 (5.6)

_

_

Table 3. ≥ Grade 3 Adverse Events

ALX148 + Trastuzumab + Ramucirumab + Paclitaxel (N=18)								
Adverse Event	Total n(%) All Causality			Total n(%) Related				
Grade	3		4		3		4	
ALX148 Dose QW	10 mg/kg	15 mg/kg	10 mg/kg	15 mg/kg	10 mg/kg	15 mg/kg	10 mg/kg	15 mg/kg
Neutrophil Count Decreased	1 (5.6)	4 (22.2)	1 (5.6)	1 (5.6)	-	-	-	-
Hypertension	2 (11.1)	4 (22.2)	-	-	-	-	-	-
Anemia	-	3 (16.7)	-	-	-	-	-	-
Fatigue	-	2 (11.1)	-	-	-	-	-	_
Hypophosphatemia	-	1 (5.6)	-	-	-	-	-	-
Lymphocyte Count Decreased	-	1 (5.6)	-	-	-	1 (5.6)	-	-
Platelet Count Decreased	-	1 (5.6)	-	-	-	-	-	-
Urinary Tract Infection	-	1 (5.6)	-	-	-	_	-	-
Aspartate Aminotransferase Increased	-	1 (5.6)	-	-	-	-	-	-
Asthenia	-	1 (5.6)	-	_	-	-	-	-
Diverticulitis	_	1 (5.6)	-	_	-	_	-	
Dysphagia	-	1 (5.6)	_	_	-	-	-	-

_

_

—




Non-Cardiac Chest Pain

_

_

ALX148 CONCENTRATION-TIME PROFILES BY DOSE LEVEL AND COMBINATION PARTNER



ALX148 PK following combination therapies with trastuzumab is comparable with and without chemotherapy (ramucirumab + paclitaxel).

RESPONSE


ALX148 Combination Expansion Cohorts – Confirmed Objective Responses in Evaluable Patients

- HER2 positive GC Expansion
 - ALX148 (15 mg/kg QW) + trastuzumab + ramucirumab + paclitaxel, ≥2L GC: N=15 [1 CR*, 10 PR, 2 SD, 2 PD].
 - ALX148 (10 mg/kg QW) + trastuzumab + ramucirumab + paclitaxel, ≥2L GC: N=3 [2 PR, 1 SD].
 - ALX148 (10 mg/kg QW) + trastuzumab, ≥2L GC: N=19 [4 PR (1 unconfirmed), 5 SD, 10 PD].

* Objective response confirmed after data cut off date.



CLINICAL ACTIVITY OF ALX148 + TRASTUZUMAB + RAMUCIRUMAB + PACLITAXEL IN PATIENTS WITH GC



ESMO-GI 2021

ALX ØNCOLOGY

CLINICAL ACTIVITY OF ALX148 COMBINATIONS IN RESPONSE EVALUABLE PATIENTS WITH ≥2L HER2 POSITIVE GC CANCER

Population	N (EVAL)	ORR (%) [95% Cl]	DOR (m) [95% Cl]	PFS (m) [95% Cl]	PFS rate at 6 m	OS (m) [95% Cl]	0S rate at 12 m	Follow up (m) [95% Cl]
≥2L Gastric (ALX-10 mg/kg or 15 mg/kg + tras/ram/pac)	18	72.2 [49.1% ; 87.5%]	NR	9.1 [3.8 ; NR]	74.5%	NR	75.8%	10.5 [4.8 ; 12.5]
Gastric (ALX-10 mg/kg + TRP)	3	66.7 [20.8% ; 93.9%]	NR	NR	100%	NR	66.7%	14.3 [12.0;NR]
Gastric (ALX-15 mg/kg + TRP)	15	73.3 [48.1% ; 89.1%]	NR	NR	68.3%	NR	80.8%	9.4 [4.2 ; 12.5]
≥2L Gastric tras/ram/paclitaxel Rha et al ASCO 2021 ³	50	52	5.1	7.4		13.6		22.9
3L Gastric Enhertu DESTINY 01 ¹	126	41	11.3	5.6	43%	12.5	52%	-
≥2L Gastric ramucirumab/paclitaxel RAINBOW-ASIA Region3 ²	109	34	0.3	5.5		12.1		7.9
≥2L Gastric (ALX-10 mg/kg + tras)	19	21.1 [8.5% ; 43.3%]	8.7 [5.6; NR]	2.2 [1.9 ; 5.5]	16.7%	8.1 [3.4 ; 12.6]	38.2%	27.0 [NR]
≥3L Gastric Irinotecan or Paclitaxel DESTINY 01ControlArm ¹	62	11.3	3.9	3.5	21%	8.4	29%	


ALX ONCOLOGY

¹Enhertu product insert, and Shitara et al, NEJM June 18, 2020; ²Wilke et al, Lancet October 2014; ³ Rha et al #4063 ASCO 2021

ESMO-GI 2021

17

BEST OVERALL AND DURATION OF RESPONSE IN PATIENTS WHILE RECEIVING ALX148 + TRASTUZUMAB + RAMUCIRUMAB + PACLITAXEL (N=18)



ALX


ØNCOLOGY

≥2L HER2 Positive GC

ESMO-GI 2021

18


CD47 TARGET OCCUPANCY FROM CHEMOTHERAPY COMBINATION COHORTS




Near complete CD47 target occupancy is maintained throughout ALX148 dosing interval over Cycles 1-3 when combined with chemotherapy-containing regimens. (For a subset of patients, target occupancy was measured up to or beyond 300 days with similar results being observed.)

ALX ØNCOLOGY

BASELINE TUMOR INFILTRATING IMMUNE CELLS IN RESPONDERS AND NON-RESPONDERS RECEIVING ALX148 (10 OR 15 MG/KG) + TRP





- Responder: CR+PR (N=7)
- Non-Responder: SD+PD (N=4)
- Plots represent mean and standard deviation.

CONCLUSIONS

Intended for combination, ALX148 exhibits favorable tolerability in combination with trastuzumab + ramucirumab + paclitaxel and demonstrates objective response in patients with GC

- Preliminary data suggest that ALX148 can be combined with trastuzumab, ramucirumab and paclitaxel with no maximum tolerated dose reached. The maximum administered dose of ALX148 in combination was 15 mg/kg QW.
- Preliminary PK/PD analysis demonstrates no impact of the combination partners upon ALX148 exposure levels with full CD47 receptor occupancy achieved and numeric increases demonstrated in % baseline tumor infiltrating immune cells in responding patients.
- ALX148 in combination with trastuzumab, ramucirumab and paclitaxel demonstrates an initial ORR of 72% and estimated OS at 12 months of 76% in patients with GCs that have progressed on or after a prior trastuzumab-containing regimen. This compares favorably with both RAINBOW⁵ and DESTINY-01⁶ randomized historical controls.
- Updated data from patients receiving ALX148 + trastuzumab after their tumors have progressed upon prior trastuzumab therapy suggests clinical activity beyond that expected from either trastuzumab or chemotherapy alone.

ACKNOWLEDGMENTS

We would like to thank all of the participating patients and their families as well as site research staff.

Contact email: info@alxoncology.com

Presented at the 2021 European Society of Medical Oncology World Congress in Gastrointestinal Cancer (ESMO-GI) Annual Meeting July 03, 2021 Abstract SO-31

¹ Weiskopf, K. *Eur J Cancer*. 2017 May;76:100-109
 ² Kauder, SE. et al. *PLoS ONE*. 2018 August;13(8): e0201832
 ³ Lakhani, N. *Journal of Clinical Oncology* 2018 36:15_suppl, 3068-3068
 ⁴ Chow et al. *Journal of Clinical Oncology* 2020 38:15_suppl, 3056-3056
 ⁵ Wilke et al, *Lancet* October 2014
 ⁶ Shitara et al, *NEJM* June 18, 2020 and Enhertu Package Insert